The Administrative Core provides the overall scientific leadership for the University of Colorado SPORE in Lung Cancer as well as providing outstanding administrative and fiscal support for the Program. The Administrative Core oversees all administrative and scientific activities of the SPORE Program;reviews and regulates financial expenditures;and prepares all reports. The Core consists of the SPORE Principal Investigator, Dr. Bunn, and the Co-PI, Dr. Miller;the SPORE Administrator, Michaela Montour;a finance specialist;and effort from the Cancer Center's grants manager, human resource manager, and operations manager for SPORE-related activities. These individuals provide a network of administrative and fiscal support to facilitate the scientific goals set by the leadership. In addition, the Administrative Core insures adherence to SPORE Guidelines, NIH policies, and other applicable federal, state and institutional policies. The Core works closely with institutional and Cancer Center leadership to insure the SPORE Program remains a priority at the institutional level;and it works closely with community advocates and fund raising groups to promote awareness of and support for the research conducted by the Program. The Core facilitates interactions with outside institutions including academic centers and industry. These interactions support visiting scientists and industry MTAs and contracts. The Core facilitates all planning and evaluation activities including the planning and support of the external and internal scientific advisory committees. The Core facilitates interactions with affiliated hospitals and medical centers including the VA Medical Center, the National Jewish Center, the University of Colorado Hospital, and institutions affiliated with the University of Colorado Comprehensive Cancer Center. Administratively, the Core performs fiscal management and oversight of the Program resources;facilitates planning and evaluation activities;schedules and staffs committees and other meetings related to the Program;exercises oversight of the other shared resource cores;disseminates information about national SPORE meetings and coordinates attendance;tracks publications by SPORE investigators;and facilitates the production of an annual progress report. The goal of these activities is the promotion of translational science that will facilitate interactions between basic and applied scientists to bring innovation to the clinic to reduce the burden of lung cancer.

Public Health Relevance

The SPORE translational research program is large with multiple projects, multiple shared resource cores, and multiple collaborations and therefore administrative support is necessary. The Administrative Core provides scientific leadership and administrative experience to support its multi-year effort including fiscal support, planning, evaluation, and outreach support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058187-19A1
Application #
8664643
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
Project End
Budget Start
2014-09-12
Budget End
2015-04-30
Support Year
19
Fiscal Year
2014
Total Cost
$162,340
Indirect Cost
$58,236
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Oweida, Ayman; Lennon, Shelby; Calame, Dylan et al. (2017) Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology 6:e1356153
Blakely, Collin M; Watkins, Thomas B K; Wu, Wei et al. (2017) Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 49:1693-1704
Tan, Aik-Choon; Vyse, Simon; Huang, Paul H (2017) Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discov Today 22:72-84
Ziemke, Michael; Patil, Tejas; Nolan, Kyle et al. (2017) Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer 109:28-35
Gao, Boning; Huang, Chunxian; Kernstine, Kemp et al. (2017) Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget 8:11114-11126
Gautschi, Oliver; Milia, Julie; Filleron, Thomas et al. (2017) Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol 35:1403-1410
Li, Howard Y; McSharry, Maria; Bullock, Bonnie et al. (2017) The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Cancer Immunol Res 5:767-777
McCoach, C E; Blumenthal, G M; Zhang, L et al. (2017) Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol 28:2707-2714
Vaishnavi, Aria; Schubert, Laura; Rix, Uwe et al. (2017) EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res 77:3551-3563
Bruno, Tullia C; Ebner, Peggy J; Moore, Brandon L et al. (2017) Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients. Cancer Immunol Res 5:898-907

Showing the most recent 10 out of 397 publications